Advarra

MARCH 31, 2023

The use of engineered genetic materials in clinical trials is rapidly expanding, with potential applications for genetic vaccines, gene-modified cellular therapies, and gene therapies. Gene Delivery Systems Genetic material, in the form of DNA or RNA, does not easily enter cells without the aid of a delivery system.

Engineer 52

Engineer Genetics Clinical Research Research 52

XTalks

MAY 29, 2024

Issues of nitrosamine contamination during manufacturing have also plagued Januvia since 2022, compounding the decline in sales. Novartis also purchased siRNA-focused DTx Pharma for $500 million upfront, which includes a preclinical therapy for an inherited neuromuscular disorder. Bristol Myers Squibb Revenue in 2023: $45.00

Pharma Companies 52

Pharma Companies Sales FDA Approval Vaccination 52

Pharmaceutical Technology

APRIL 27, 2023

GlobalData pharmaceutical analysts project that RNA-based gene therapies for oncology will grow from zero in 2022 to $4.6 Every stage of development should result in a reproducible, safe drug product with no cross contamination from one batch to another. billion by 2028. This is what SUT offers.”

Manufacturing 130

Manufacturing RNA Contamination Vaccination 130

XTalks

JANUARY 6, 2025

From leveraging artificial intelligence (AI) to streamline diagnostics and treatments to exploring the untapped potential of RNA-based therapeutics, biotechnology is shaping the future of healthcare and beyond. As of January 31, 2024, approximately 131 unique RNA-based therapies are in clinical development across various therapeutic areas.

Gene Therapy 111

Gene Therapy RNA Gene Editing Gene 111